Hester Biosciences Appoints Ashish Desai as New Chief Financial Officer

Hester Biosciences Limited , a prominent player in the biosciences sector, has announced a significant change in its top management. The company has appointed Mr. Ashish Desai as its new Chief Financial Officer (CFO) and Key Managerial Personnel, effective from 20 November 2025.

Appointment Details

The appointment of Mr. Desai was approved by the Board of Directors through a circulation of resolution, based on recommendations from both the Nomination and Remuneration Committee and the Audit Committee. This decision aligns with the company's commitment to strengthening its financial leadership.

About Ashish Desai

Mr. Desai brings a wealth of experience to his new role:

Aspect	Details
Previous Position	Group Finance Controller at Hester Biosciences
Total Experience	Over 25 years in finance
Areas of Expertise	Accounting, budgeting, auditing, finance, costing, and taxation
Educational Background	Chartered Accountant, Bachelor's degree in Commerce from Gujarat University
Key Achievements	Led initiatives in financial restructuring, trade finance, treasury management, cost optimization, and organizational development
Prior Roles	CFO at Blue Ray Aviation Private Limited and Shreeyam Power & Steel Industries Limited (a listed company with INR 1,200.00 crore turnover)

Implications for Hester Biosciences

Mr. Desai's appointment as CFO is expected to bring valuable financial acumen to Hester Biosciences. His extensive experience in various aspects of finance, including his tenure as Group Finance Controller within the company, positions him well to lead the financial operations of Hester Biosciences.

This strategic move comes at a time when companies are increasingly focusing on robust financial management and strategic financial planning. Mr. Desai's appointment may signal Hester Biosciences' intent to further strengthen its financial processes and potentially explore new growth opportunities.

As Hester Biosciences continues to navigate the dynamic biosciences sector, Mr. Desai's leadership in the finance department will be crucial in supporting the company's overall strategic objectives and maintaining its competitive edge in the market.

The company has complied with all necessary regulatory disclosures regarding this appointment, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.34%	-1.10%	+0.35%	-9.13%	-38.14%	-7.84%

Hester Biosciences Limited , a prominent player in the animal healthcare sector, has announced a significant change in its top management. The company's Chief Financial Officer (CFO), Divyesh Maru, has submitted his resignation, set to take effect on November 13, 2025.

Key Details of the Resignation

Particulars	Details
Position Resigned	Chief Financial Officer and Key Managerial Personnel
Effective Date	November 13, 2025 (close of office hours)
Reason for Resignation	To pursue other career interests

Transition Period and Company Response

The early announcement of Maru's departure, nearly two years in advance, provides Hester Biosciences with ample time to ensure a smooth transition of financial leadership responsibilities. This extended notice period is likely to facilitate a comprehensive handover process and allow the company to conduct a thorough search for a suitable replacement.

In its official communication to the stock exchanges, Hester Biosciences expressed gratitude for Maru's contributions during his tenure as CFO. The company has not yet announced any plans regarding Maru's successor.

Regulatory Compliance

The resignation was disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Hester Biosciences has duly informed both the BSE Limited and the National Stock Exchange of India Limited about this development.

Impact on Hester Biosciences

While leadership changes can often lead to short-term uncertainties, the extended transition period in this case may help mitigate potential disruptions to the company's financial operations. Investors and stakeholders will likely be watching closely for announcements regarding Maru's successor and any potential shifts in financial strategy.

As Hester Biosciences navigates this transition, the company's ability to maintain financial stability and continue its growth trajectory will be of key interest to market observers and shareholders alike.